Vietnam Pharmaceutical Joint Stock Company

Vietnam Pharmaceutical Joint Stock Company
Vietnam Pharmaceutical Joint Stock Company

Leaders of Vietnam Pharmaceutical Joint Stock Company said that the company’s profit plan for the period of 2023-2023 is highly feasible.

Specifically, in 2023, the Company sets a revenue target of VND 1,251 billion, profit after tax of VND 60.8 billion, increasing by 6% and 11.7% respectively compared to the results achieved in 2022.

According to DVM, as of December 31, 2023, the company has 19 distribution pharmacies located in hospitals (2 provincial pharmacies, 17 district pharmacies) and one retail pharmacy that meets GPP standards. In addition to the plan to expand more pharmacies at the provincial, district and retail levels, the company also plans to develop a drugstore system with a total of 52 pharmacies in 2023, 44 pharmacies in 2024 and 2025. 35 pharmacies. In total, in the next 3 years, the company plans to operate 131 pharmacies.

Regarding specific goals with the bidding block, the company sets a growth target of 5%/year for 2023 with all items such as medicinal herbs, modern drugs, consumables and maintaining stability for the following years. . It is expected that cancer drug products will be distributed through the bidding block starting from 2024 exactly as the consumption schedule has been built in the project.

Regarding the OTC segment, the company sets a target of OTC sales at VND 572 billion in 2023 with a growth rate of 5% for new pharmaceutical products, consumables, and food products. For health care, preliminarily processed medicinal herbs, target sales growth of 3% to focus on improving gross profit margin to make OTC block the most effective business in the three blocks for home-made products. factory.

In the pharmacy sector, the plan is that the total revenue of drugstores will decrease from 23.7% to 13% to match the consumption market.

In 2023-2025, the company sets a revenue target of VND 1,251 billion in 2023, VND 1,339 billion in 2024 and VND 1,459 billion in 2025, with an annual growth rate of 7%-9%.

Regarding profit after tax in the period of 2023-2025, the Company targets a profit of 60.8 billion dong in 2023, 70.5 billion dong in 2023 and 81.7 billion dong in 2025. The annual profit growth rate reaches 15%-16%.

Company leaders also said that the profit plan for the period of 2023-2023 is highly feasible. The domestic pharmaceutical industry is benefiting from the Government’s development orientation to encourage the production and use of drugs in the country.

In addition, the company also has the policy of expanding investment in production lines, as well as speeding up the progress of completing the construction of new drugstores, promoting the consumption of products manufactured by the company’s factory. If there are no unexpected force majeure fluctuations such as natural disasters, epidemics affecting business activities, the company will achieve the set plan.

In addition, Vietnam Pharmaceuticals also plans to offer 17,825,000 shares to the public. Release time in the fourth quarter of 2023 or the first and second quarters of 2024. Expected charter capital after the offering is VND 606.05 billion.

The capital obtained from the capital increase (expected VND 178.25 billion), the Company will invest in the project “Investing in standard warehouses and completing the production line of infusion solutions”. In case the project is not approved by the General Meeting of Shareholders, the Board of Directors will use the proceeds for other purposes such as supplementing working capital, repaying loans, etc.

At the end of the first quarter of 2023, DVM achieved revenue of more than 246 billion VND and profit after tax of more than 11.7 billion VND, completing more than 19% of the plan in terms of revenue and profit for the whole year.

Hai Minh

The article is in Vietnamese

Tags: Vietnam Pharmaceutical Joint Stock Company


PREV Five groups of issues to be questioned at the National Assembly
NEXT ‘Digitalizing’ the logistics industry to meet the new requirements of the market